Abstract
Angiogenesis is a key step in tumor growth and metastasis. The mechanism by which osteopontin (OPN) induces the angiogenesis of endothelial cells remains unclear. Here, we show that OPN confers cytoprotection through the activation of the PI3K/Akt pathway with subsequent upregulation of Bcl-xL and activation of nuclear factor-κB. OPN enhances the expression of vascular endothelial growth factor (VEGF) through the phosphorylation of AKT and extracellular signal-regulated kinase (ERK). In turn, OPN-induced VEGF activates PI3K/AKT and the ERK1/2 pathway as a positive feedback signal. Blocking the feedback signal by anti-VEGF antibody, PI3-kinase inhibitor or ERK inhibitor can partially inhibit the OPN-induced human umbilical vein endothelial cell (HUVEC) motility, proliferation and tube formation, while blocking the signal by anti-OPN or anti-αvβ3 antibody completely abrogates the biological effects of OPN on HUVECs. In addition, blood vessel formation is also investigated in vivo. The antiangiogenesis efficacy of anti-OPN antibody in vivo is more effective than that of anti-VEGF antibody, which only blocks the feedback signals. These data show that OPN enhances angiogenesis directly through PI3K/AKT- and ERK-mediated pathways with VEGF acting as a positive feedback signal. The results suggest that OPN might be a valuable target for developing novel antiangiogenesis therapy for treatment of cancer.
Similar content being viewed by others
References
Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E . (1995). Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024–1028.
Asano M, Yukita A, Matsumoto T, Kondo S, Suzuki H . (1995). Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res 55: 5296–5301.
Beraud C, Henzel WJ, Baeuerle PA . (1999). Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-κB activation. Proc Natl Acad Sci USA 96: 429–434.
Brady H, Desai S, Gayo-Fung LM, Khammungkhune S, McKie JA et al. (2002). Effects of SP50 a novel, potent antiestrogen, on breast cancer cells and in xenograft models. Cancer Res 62: 1439–1442.
Cao Z, Dai J, Fan K, Wang H, Ji G, Li B et al. (2008). A novel functional motif of osteopontin for human lymphocyte migration and survival. Mol Immunol 45: 3683–3692.
Chakraborty G, Jain S, Kundu GC . (2008). Osteopontin promotes vascular endothelial growth factor–dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res 68: 152–161.
Das R, Mahabeleshwar GH, Kundu GC . (2003). Osteopontin stimulates cell motility and nuclear factor kB- mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-Kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278: 28593–28606.
Denhardt DT, Chambers AF . (1994). Overcoming obstacles to metastasis-defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 56: 48–51.
Denhardt DT . (1996). Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Crit Rev Oncog 7: 261–291.
Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS . (2001). Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055–1061.
Folkman J, Watson K, Ingber D, Hanahan D . (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58–61.
Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al. (1998). Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 273: 30336–30343.
Hanahan D, Folkman J . (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353–364.
Jain S, Chakraborty G, Kundu GC . (2006). The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis. Cancer Res 66: 6638–6648.
Javerzat S, Auguste P, Bikfalvi A . (2002). The role of fibroblast growth factors in vascular development. Trends Mol Med 8: 483–489.
Kane LP, Shapiro VS, Stokoe D, Weiss A . (1999). Induction of NF-κB by the Akt/PKB kinase. Curr Biol 9: 601–604.
Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT . (2002). Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cell Biochem 85: 728–736.
Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, Hermann DM . (2006). The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J 20: 1185–1187.
Kwak HJ, So JN, Lee SJ, Kim I, Koh GY . (1999). Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 448: 249–253.
L'Hôte CG, Knowles MA . (2005). Cell responses to FGFR3 signaling: growth, differentiation and apoptosis. Exp Cell Res 304: 417–431.
Nishiyama K, Takaji K, Kataoka K, Kurihara Y, Yoshimura M, Kato A et al. (2005). Id1 gene transfer confers angiogenic property on fully differentiated endothelial cells and contributes to therapeutic angiogenesis. Circulation 112: 2840–2850.
Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE et al. (2000). Akt/Protein kinase B upregulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275: 10761–10766.
Rittling SR, Chambers AF . (2004). Role of osteopontin in tumor progression. Br J Cancer 90: 1877–1881.
Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M . (1996). Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol 149: 293–305.
Shiojima I, Walsh K . (2002). Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 90: 1243–1250.
Shijubo N, Kojima H, Nagata M, Ohchi T, Suzuki A, Abe S et al. (2003). Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech 60: 186–198.
Solorzano CC, Jung YD, Bucana CD et al. (2001). In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res 61: 7048–7051.
Standal T, Borset M, Sundan A . (2004). Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26: 179–184.
Toshifumi S, Ulises A, Hruska KA . (2003). PTEN regulates RANKL- and osteopontin-stimulated signal transduction during osteoclast differentiation and cell motility. J Biol Chem 278: 5001–5008.
Tuck AB, Chambers AF, Allan AL . (2007). Osteopontin overexpression in breast cancer: knowledge gained and possible implications for clinical management. J Cell Biochem 102: 859–868.
Weidner N . (1995). Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 36: 169–180.
Wu LW, Mayo LD, Dunbar JD, Kessler KM, Baerwald MR, Jaffe EA et al. (2000). Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J Biol Chem 18: 275:5096–275:5103.
Xu G, Nie H, Li N, Ni L, Xu R, Hong J et al. (2005). Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J Clin Invest 115: 1060–1067.
Acknowledgements
This study was supported in part by the grants from the National Natural Science Foundation of China, Shanghai Commission of Science and Technology, Ministry of Science and Technology of China (973 and 863 projects), Shanghai Commission of Education as well as a special grant from Shanghai Pudong Bureau of Science and Technology of China. JX Dai is a recipient of ‘Pujiang’ Research Scholarship from Shanghai Commission of Education.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Supplementary information
Rights and permissions
About this article
Cite this article
Dai, J., Peng, L., Fan, K. et al. Osteopontin induces angiogenesis through activation of PI3K/AKT and ERK1/2 in endothelial cells. Oncogene 28, 3412–3422 (2009). https://doi.org/10.1038/onc.2009.189
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.189
- Springer Nature Limited
Keywords
This article is cited by
-
Oral cancer cell to endothelial cell communication via exosomal miR-21/RMND5A pathway
BMC Oral Health (2024)
-
Osteopontin secreted from obese adipocytes enhances angiogenesis and promotes progression of pancreatic ductal adenocarcinoma in obesity
Cellular Oncology (2024)
-
Osteopontin: A Novel Therapeutic Target for Respiratory Diseases
Lung (2024)
-
Serum osteopontin predicts the response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Journal of Gastroenterology (2023)
-
CRISPR/Cas9 mediated knocking out of OPN gene enhances radiosensitivity in MDA-MB-231 breast cancer cell line
Journal of Cancer Research and Clinical Oncology (2023)